skip to main content
Idioma:
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials

Kang, Dongyu ; Jing, Zhihui ; Li, Ranran ; Hei, Gangrui ; Shao, Tiannan ; Li, Li ; Sun, Mengxi ; Yang, Ye ; Wang, Ying ; Wang, Xiaoyi ; Long, Yujun ; Huang, Xiansheng ; Wu, Renrong

Frontiers in psychiatry, 2018-11, Vol.9, p.620-620 [Periódico revisado por pares]

Switzerland: Frontiers Research Foundation

Texto completo disponível

Citações Citado por
  • Título:
    Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials
  • Autor: Kang, Dongyu ; Jing, Zhihui ; Li, Ranran ; Hei, Gangrui ; Shao, Tiannan ; Li, Li ; Sun, Mengxi ; Yang, Ye ; Wang, Ying ; Wang, Xiaoyi ; Long, Yujun ; Huang, Xiansheng ; Wu, Renrong
  • Assuntos: Antipsychotic drugs ; antipsychotic medication ; betahistine ; Bipolar disorder ; BMI ; Clinical trials ; Insulin resistance ; Metformin ; Product development ; Psychiatry ; Schizophrenia
  • É parte de: Frontiers in psychiatry, 2018-11, Vol.9, p.620-620
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    This article was submitted to Schizophrenia, a section of the journal Frontiers in Psychiatry
    Reviewed by: Giuseppe Carrà, Università degli studi di Milano Bicocca, Italy; Chunbo Li, School of Medicine, Shanghai Jiao Tong University, China
    Edited by: Błazej Misiak, Wroclaw Medical University, Poland
  • Descrição: Antipsychotic-induced weight gain is one of the most common adverse effects of antipsychotic treatment. However, there are no well-established interventions for the weight gain yet. In this study, we pooled the data from two clinical trials, which were originally examining the efficacy of betahistine and the efficacy of metformin in treating antipsychotic-induced weight gain and insulin resistance. A total of 67 people with schizophrenia or bipolar disorder treated with antipsychotics were assigned to 36 mg day betahistine ( = 13) or 1,000 mg day metformin ( = 25) or placebo ( = 29) treatment for 12 weeks, with evaluation at baseline and week 12. The primary outcome was the body mass index (BMI). After treatment, metformin group had a mean decrease in BMI of 1.46 ± 0.14 ( < 0.001) and insulin resistance index (IRI) of 4.30 ± 2.02 ( < 0.001). The betahistine group had no significant alteration in BMI or IRI. However, placebo group had a mean increase in BMI of 1.27 ± 0.77 ( < 0.001) and IRI of 0.45 ± 0.86 ( < 0.001). Between the two treatment groups, metformin significantly decreased weight, BMI, fasting glucose, insulin level, and IRI but not waist circumference when compared with betahistine. Moreover, metformin significantly decreased weight, BMI, waist circumference, fasting glucose, insulin level, and IRI when compared with placebo, whereas betahistine significantly decreased body weight, waist circumference, BMI, insulin level, and IRI but not fasting glucose when compared with placebo. In this study, we found that both metformin treatment and betahistine treatment were efficacious in improving antipsychotic-induced weight gain and insulin resistance, and metformin was more efficacious in preventing and revising the weight gain induced by antipsychotics. www.ClinicalTrials.gov, NCT00451399(Study 1), NCT00709202(Study 2).
  • Editor: Switzerland: Frontiers Research Foundation
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.